CAMP4 Therapeutics Corp (NASDAQ: CAMP)’s stock price has plunge by 170358relation to previous closing price of 1.4. Nevertheless, the company has seen a 1.95% surge in its stock price over the last five trading sessions. globenewswire.com reported 2025-05-16 that Haploinsufficient SYNGAP1 mice treated with CMP-SYNGAP-01 demonstrated an increase in SYNGAP1 protein levels; treatment rescued multiple SYNGAP1-dependent behavioral phenotypes
Is It Worth Investing in CAMP4 Therapeutics Corp (NASDAQ: CAMP) Right Now?
Analysts have varying opinions on the stock, with 3 analysts rating it as a “buy,” 2 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for CAMP is 2.64M and currently, short sellers hold a 18.61% of that float. On June 24, 2025, CAMP’s average trading volume was 292.47K shares.
CAMP’s Market Performance
The stock of CAMP4 Therapeutics Corp (CAMP) has seen a 1.95% increase in the past week, with a -20.71% drop in the past month, and a -70.15% fall in the past quarter. The volatility ratio for the week is 6.84%, and the volatility levels for the past 30 days are at 4.28% for CAMP. The simple moving average for the last 20 days is -11.02% for CAMP stock, with a simple moving average of -68.64% for the last 200 days.
Analysts’ Opinion of CAMP
Many brokerage firms have already submitted their reports for CAMP stocks, with Wedbush repeating the rating for CAMP by listing it as a “Outperform.” The predicted price for CAMP in the upcoming period, according to Wedbush is $8 based on the research report published on May 27, 2025 of the current year 2025.
Piper Sandler gave a rating of “Overweight” to CAMP, setting the target price at $18 in the report published on November 05th of the previous year.
CAMP Trading at -17.52% from the 50-Day Moving Average
After a stumble in the market that brought CAMP to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -87.24% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CAMP starting from Northpond Ventures II GP, LLC, who purchase 763,636 shares at the price of $11.00 back on Oct 15 ’24. After this action, Northpond Ventures II GP, LLC now owns 763,636 shares of CAMP4 Therapeutics Corp, valued at $8,399,996 using the latest closing price.
AH Equity Partners Bio I, L.L., the 10% Owner of CAMP4 Therapeutics Corp, purchase 727,272 shares at $11.00 during a trade that took place back on Oct 15 ’24, which means that AH Equity Partners Bio I, L.L. is holding 1,579,885 shares at $7,999,992 based on the most recent closing price.
Stock Fundamentals for CAMP
Current profitability levels for the company are sitting at:
- -35.31 for the present operating margin
- 0.72 for the gross margin
The net margin for CAMP4 Therapeutics Corp stands at -34.29. The total capital return value is set at -0.95.
Based on CAMP4 Therapeutics Corp (CAMP), the company’s capital structure generated 0.13 points at debt to capital in total, while cash flow to debt ratio is standing at -6.19.
Currently, EBITDA for the company is -51.39 million with net debt to EBITDA at 0.8. When we switch over and look at the enterprise to sales, we see a ratio of -6.49. The receivables turnover for the company is 14.25for trailing twelve months and the total asset turnover is 0.02. The liquidity ratio also appears to be rather interesting for investors as it stands at 8.02.
Conclusion
To wrap up, the performance of CAMP4 Therapeutics Corp (CAMP) has been bad in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
